Amey Chalke

Jump to

Earnings will see some impact if Divi's Unit 2 does not get cleared by USFDA: Analyst

The ongoing re-inspection at Unit 2 of Divi's Laboratories remains in focus. In an interview to CNBC-TV18, Amey Chalke of HDFC Securities shared his expectations.
Expect 15-20% cut in Divis Labs' FY18-FY19 EPS estimates: HDFC Sec

In an interview to CNBC-TV18, Amey Chalke, Pharma Analyst at HDFC Securities shared his readings and outlook on Divis Laboratories and Dr Reddys Laboratories.
Analysts give a thumbs-up to Cadila on resolution of FDA warning

Brokerage firms and analysts tracking the stock welcomed the development and most have raised the target price. To be sure a lot of them were expecting resolution of the warning letter on Moraiya facility in the fourth quarter of FY17.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347

Amey Chalke

Earnings will see some impact if Divi's Unit 2 does not get cleared by USFDA: Analyst

Expect 15-20% cut in Divis Labs' FY18-FY19 EPS estimates: HDFC Sec

Analysts give a thumbs-up to Cadila on resolution of FDA warning